[Synthetic human insulin and diabetes mellitus: immunologic aspects].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to G Guglielmi.
Explore the source record for details and available documents.
The uptake of 97Ru-transferrin (Ru-TF) in tumor and abscess bearing animals was compared with 67Ga-citrate (Ga), 123I-transferrin (I-TF), and several other plasma proteins. Maximal concentration in tumor of Ru-TF in mice was three times higher than 67Ga-citrate (16.80 +/- 4.20 vs 5.08 +/- 0.58% D/g) although it occurred later (24 h compared with 67Ga which reached its maximum 2 h after injection). Whole body autoradiography (WBARG) with 103Ru-transferrin (103Ru-TF) in tumor and abscess bearing rats demonstrated details of the distribution within these lesions. Turpentine-induced abscesses in the rabbits could be visualized with the gamma camera as early as 30 min post-injection of Ru-TF. It seems, therefore, that Ru-TF can be used for tumor and abscess localization. The results indicate that Ru-TF may have some advantages over 67Ga-citrate because of the higher concentration in the lesions. 123I-transferrin reached a concentration in tumor similar to 67Ga (6.89 +/- 1.67 vs 5.08 +/- 0.58% D/g) but had a very low tumor to blood ratio (0.64). The three compounds investigated (Ru-TF, I-TF and ionic Ga, which binds instantaneously to TF in vivo) have a common ligand, transferrin. It appears, therefore, that tumor affinity is a property of the radionuclide-ligand complex rather than of the radionuclide itself.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
N-Methyl-N-(beta-hydroxyethyl) guanidine O-phosphate (creatinol O-phosphate, COP) was checked on patients suffering from inadequate coronary circulation (12 patients had a recent myocardial infarction and 13 were suffering from angina pectoris) versus a reference substance (solvent of COP) in a double blind study. COP improved rhythm disturbances, chest pains and symptoms of contractility failure to a statistically significant degree.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.